Udvalget anbefaler derfor, at markedsføringstilladelserne opretholdes for alle veterinærlægemidler, der henvises til i Bilag I, og at markedsføringstilladelserne ændres, så indikationer og dosisregimer harmoniseres som beskrevet i ovenstående afsnit.
Therefore the Committee recommends maintaining the Marketing Authorisations for all veterinary medicinal products as referred to in Annex I and to vary the Marketing Authorisations in order to harmonise the indications and dosing regimens as described in the paragraph above.